Conditional survival analysis of patients with resected non-small cell lung cancer

被引:0
|
作者
Chaudhry, Talib [1 ]
Krishnan, Vaishnavi [1 ]
Donaldson, Andrew E. [1 ]
Palmisano, Zachary M. [1 ]
Basu, Sanjib [1 ]
Geissen, Nicole M. [1 ]
Karush, Justin M. [1 ]
Alex, Gillian C. [1 ]
Borgia, Jeffrey A. [2 ,3 ]
Liptay, Michael J. [1 ]
Seder, Christopher W. [1 ]
机构
[1] Rush Univ, Med Ctr, Dept Cardiovasc & Thorac Surg, Joan & Paul Rubschlager Bldg,6th Floor,1520 W Harr, Chicago, IL 60612 USA
[2] Rush Univ, Med Ctr, Dept Pathol, Chicago, IL USA
[3] Rush Univ, Med Ctr, Dept Anat & Cell Biol, Chicago, IL USA
来源
JTCVS OPEN | 2023年 / 16卷
关键词
non-small cell lung cancer; conditional sur- vival; conditional survival; prognosis; LONG-TERM SURVIVAL; RECURRENCE; PROBABILITY;
D O I
10.1016/j.xjon.2023.09.010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Conditional survival (CS) analyses provide an estimate of survival accounting for years already survived after treatment. We aim to evaluate the difference between actuarial and conditional survival in patients following lung resection for non-small - small cell lung cancer (NSCLC). In addition, CS analyses are used to examine whether prognosticators of survival change over time following surgery. Methods: Patients who underwent anatomic lung resection at a single institution for pathologic stage I-IIIA NSCLC between 2010 and 2021 were identified; those who underwent wedge resection for node-negative tumors < 2 cm were also included. CS estimates were calculated as the probability of remaining disease- free after x years of nonrecurrence (CSx). Kaplan-Meier, log-rank, and Cox proportional hazard methods for examining CS were used for subgroup comparisons and assessing associations with baseline covariates. Results: Overall, 863 patients met the study inclusion criteria, with a median followup of 44.1 months. Conditional overall survival (OS) and disease-free survival (DFS) were greater than actuarial rates at all time points after surgery. At the time of resection, male sex (hazard ratio [HR], 1.33; 95% % confidence interval [CI], 1.03 to 1.72; P = .032), tumor size>3 cm (HR, 1.17; 95% % CI, 1.11-1.23; P < .001), node positivity (HR, 3.31; 95% % CI, 2.52-4.33; P < .001), and American Joint Committee on Cancer stage (P < .001) were associated with DFS. However, if a patient lived 3 years without recurrence (CS3), these factors were no longer prognostic of DFS. Conclusions: Conditional survival analyses provide dynamic assessments of OS and DFS after NSCLC resection. After 3 years without recurrence, certain characteristics associated with DFS at the time of surgery no longer prognosticate recurrence. (JTCVS Open 2023;16:948-59)
引用
收藏
页码:948 / 959
页数:12
相关论文
共 50 条
  • [21] Predictors of Survival in Patients With Non-Small Cell Lung Cancer
    Luo, Juhua
    Chen, Yea-Jyh
    Narsavage, Georgia L.
    Ducatman, Alan
    ONCOLOGY NURSING FORUM, 2012, 39 (06) : 609 - 616
  • [22] Predictive survival markers in patients with surgically resected non-small cell lung carcinoma
    Moldvay, J
    Scheid, P
    Wild, P
    Nabil, K
    Siat, J
    Borrelly, J
    Marie, B
    Farré, G
    Labib, T
    Pottier, G
    Sesboüé, R
    Bronner, C
    Vignaud, JM
    Martinet, Y
    Martinet, N
    CLINICAL CANCER RESEARCH, 2000, 6 (03) : 1125 - 1134
  • [23] Adjuvant chemotherapy in patients with completely resected non-small cell lung cancer
    Pirker, Robert
    TRANSLATIONAL LUNG CANCER RESEARCH, 2014, 3 (05) : 305 - 310
  • [24] Prognosis of resected non-small cell lung cancer patients with intrapulmonary metastases
    Nagai, Kanji
    Sohara, Yasunori
    Tsuchiya, Ryosuke
    Goya, Tomoyuki
    Miyaoka, Etsuo
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (04) : 282 - 286
  • [25] Effects of Postoperative Radiotherapy on Survival of Patients With Stage IIIA Resected Non-Small Cell Lung Cancer: Analysis of the SEER Database
    Gao, Fei
    Li, Nan
    Xu, YongMei
    Yang, GuoWang
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2020, 18 (06): : 718 - +
  • [26] Adjuvant chemotherapy for resected non-small cell lung cancer
    Booth, Christopher M.
    Shepherd, Frances A.
    JOURNAL OF THORACIC ONCOLOGY, 2006, 1 (02) : 180 - 187
  • [27] Adjuvant Chemotherapy for Resected Non-Small Cell Lung Cancer
    Wakelee, Heather
    Chhatwani, Laveena
    SEMINARS IN THORACIC AND CARDIOVASCULAR SURGERY, 2008, 20 (03) : 198 - 203
  • [28] Prediction of recurrence and survival using PET SUV max in patients with resected non-small cell lung cancer
    Lam, Wei-Sen
    Savage, Claire
    Hung, Terry
    McMullen, Michelle
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 159 - 159
  • [29] Evaluation of tumor infiltrating lymphocites (TILs) and survival in patients with resected non-small cell lung cancer.
    Cardenas Quesada, Nuria
    Ortega Granados, Ana Laura
    Marquez Lobo, Belgica
    Rosa Garrido, Carmen
    Sanchez Rovira, Pedro
    Nunez Torres, Maria Isabel
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [30] An association between DNA repair gene polymorphisms and survival in patients with resected non-small cell lung cancer
    Butkiewicz, Dorota
    Rusin, Marek
    Sikora, Bozena
    Lach, Antonina
    Chorazy, Mieczyslaw
    MOLECULAR BIOLOGY REPORTS, 2011, 38 (08) : 5231 - 5241